A phase II trial of high-dose bromodeoxyuridine with accelerated fractionation radiotherapy followed by procarbazine, lomustine, and vincristine for glioblastoma multiforme

Απλή σελίδα τεκμηρίου
dc.contributor.authorGroves, M. D.en
dc.contributor.authorMaor, M. H.en
dc.contributor.authorMeyers, C.en
dc.contributor.authorKyritsis, A. P.en
dc.contributor.authorJaeckle, K. A.en
dc.contributor.authorYung, W. K.en
dc.contributor.authorSawaya, R. E.en
dc.contributor.authorHess, K.en
dc.contributor.authorBruner, J. M.en
dc.contributor.authorPeterson, P.en
dc.contributor.authorLevin, V. A.en
dc.date.accessioned2015-11-24T19:39:57Z
dc.date.available2015-11-24T19:39:57Z
dc.identifier.issn0360-3016-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/24282
dc.rightsDefault Licence-
dc.subjectAdulten
dc.subjectAgeden
dc.subjectAntimetabolites, Antineoplastic/administration & dosage/adverse effectsen
dc.subjectAntineoplastic Combined Chemotherapy Protocols/*administration & dosage/adverseen
dc.subjecteffectsen
dc.subjectBrain Neoplasms/*drug therapy/pathology/*radiotherapy/surgeryen
dc.subjectBromodeoxyuridine/administration & dosage/adverse effectsen
dc.subjectCognition/drug effects/radiation effectsen
dc.subjectCombined Modality Therapyen
dc.subjectDisease Progressionen
dc.subjectDisease-Free Survivalen
dc.subjectFemaleen
dc.subjectGlioblastoma/*drug therapy/pathology/*radiotherapy/surgeryen
dc.subjectHumansen
dc.subjectLomustine/administration & dosage/adverse effectsen
dc.subjectMaleen
dc.subjectMiddle Ageden
dc.subjectProcarbazine/administration & dosage/adverse effectsen
dc.subjectRadiation-Sensitizing Agents/*administration & dosage/adverse effectsen
dc.subjectReoperationen
dc.subjectVincristine/administration & dosage/adverse effectsen
dc.titleA phase II trial of high-dose bromodeoxyuridine with accelerated fractionation radiotherapy followed by procarbazine, lomustine, and vincristine for glioblastoma multiformeen
heal.abstractPURPOSE: To conduct a Phase II study to evaluate the long-term efficacy and safety of high-dose 5'-bromodeoxyuridine (BrdU) and accelerated radiotherapy followed by procarbazine, lomustine (CCNU), and vincristine (PCV) chemotherapy in patients with glioblastoma multiforme. METHODS AND MATERIALS: Between 1994 and 1996, 88 patients were enrolled to receive 1.9 Gy of radiation three times a day for two 5-day cycles separated by 2 weeks; each 5-day cycle was preceded by a continuous 96-hour infusion of BrdU at a dose of 2.1 g/m2/day. After radiotherapy, patients received PCV chemotherapy. RESULTS: Median survival for all 88 patients was 50 weeks. Seventy (79.5 %) received one or more courses of PCV; their median survival was 57 weeks. Covariates predictive of improved survival were gross total versus subtotal resection or biopsy (p = 0.0048) and radiation dose > or = 56 Gy (p = 0.019). While receiving BrdU, 47 patients (53%) suffered grade 3 or 4 thrombocytopenia or leukopenia; 22 patients (25%) suffered grade 3 or 4 dermatologic toxicity. CONCLUSION: Survival was not extended in patients with glioblastoma or gliosarcoma who received BrdU at the dose and administration schedule used in this study. The BrdU dose used in this study resulted in substantial myelosuppressive and dermatologic toxicity.en
heal.accesscampus-
heal.fullTextAvailabilityTRUE-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/10477016-
heal.journalNameInt J Radiat Oncol Biol Physen
heal.journalTypepeer-reviewed-
heal.languageen-
heal.publicationDate1999-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.typejournalArticle-
heal.type.elΆρθρο Περιοδικούel
heal.type.enJournal articleen

Αρχεία

Φάκελος/Πακέτο αδειών

Προβολή: 1 - 1 of 1
Μικρογραφία εικόνας
Ονομα:
license.txt
Μέγεθος:
1.74 KB
Μορφότυπο:
Item-specific license agreed upon to submission
Περιγραφή:
Κατεβάστε

Συλλογές

Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ